Neil Mushlin, DO
Pulmonary Disease · Lansdale, PANPI 1639387418
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $247,758 of the $360,127 with a category attached, or 68.8%. It is spread thinly across 52 manufacturers, the largest accounting for just 19.3%. Reporting peaked in 2021 at $108,375 and has fallen 68.7% since, to $33,952 in 2025. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,900 payments — averaging $124.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Advanced Respiratory, Inc$69K
- Jazz Pharmaceuticals Inc.$48K
- AstraZeneca$45K
- Baxter Healthcare$44K
- Mallinckrodt Hospital Products Inc.$33K
- Genentech USA, Inc.$27K
- plus $94K from 46 others
What the payments were for
- Consulting fees$55,12615%
- Speaking & faculty fees$247,75869%
- Travel & lodging$220%
- Food & beverage$56,28616%
- Education$9350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Life 2000 Ventilation System$64,703
- ACTHAR$49,385
- XYWAV$38,099
- XOLAIR$26,570
- Wakix$23,049
- Hillrom - Volara System$22,440
- Hillrom - Life 2000 Ventilation System$21,930
- The Monarch Airway Clearance System$18,290
- The Vest System 205 Acute Care$18,290
- Volara System$16,970
- SynclaraCough System$16,970
- AIRSUPRA$15,810
- TEZSPIRE$13,198
- Hillrom - Vest System Model 105 Home Care$12,465
- Prolastin-C Liquid$11,663
- Ohtuvayre$6,875
- XYREM$3,655
- Hillrom - Vest System Model 205 Acute Care$3,285
- FASENRA$3,038
- BREZTRI$2,822
How this compares
$360,127 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 40 | $730,820 |
| WakixPitolisant Hcl | 49 | $457,716 |
| OfevNintedanib Esylate | 37 | $314,123 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 184 | $202,901 |
| LumryzSodium Oxybate | 12 | $173,382 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 19 | $167,288 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 164 | $149,691 |
| Pirfenidone | 37 | $126,022 |
| FasenraBenralizumab | 12 | $69,224 |
| XolairOmalizumab | 19 | $64,333 |
| SunosiSolriamfetol Hcl | 43 | $41,904 |
| Spiriva RespimatTiotropium Bromide | 42 | $41,340 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $28,821 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $28,741 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $13,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $25,509 | $457,71649 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $2,071 | $369,04296 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $5,995 | $260,463288 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Symbicort | $45,367 | $225,053190 claims |
| Avadel CNS Pharmaceuticals, LLCLumryz | $1,041 | $173,38212 claims |
| Grifols USA, LLCProlastin C | $11,948 | $167,28819 claims |
| Genentech, Inc.Xolair | $54 | $64,33319 claims |
| Axsome Therapeutics, Inc.Sunosi | $2,290 | $41,90443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Lansdale
- Nina MaouelaininLansdale$61K
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.